The Food and Drug Administration’s Office of Generic Drugs program funded approximately $20 million in generic drug science and research programs in 2021.
The first generic of Restasis is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Avalere’s examination of Medicare Part D plan tier placement of generic prescription drugs found that over time their percentage on generic tiers has declined from 65% in 2016 to 43% in 2022.